B

Bioventus Inc
NASDAQ:BVS

Watchlist Manager
Bioventus Inc
NASDAQ:BVS
Watchlist
Price: 8.07 USD -5.28% Market Closed
Market Cap: $667.9m

Bioventus Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Bioventus Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
B
Bioventus Inc
NASDAQ:BVS
Inventory
$96.3m
CAGR 3-Years
8%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Haemonetics Corp
NYSE:HAE
Inventory
$321.2m
CAGR 3-Years
8%
CAGR 5-Years
1%
CAGR 10-Years
5%
ICU Medical Inc
NASDAQ:ICUI
Inventory
$622.4m
CAGR 3-Years
0%
CAGR 5-Years
14%
CAGR 10-Years
31%
Align Technology Inc
NASDAQ:ALGN
Inventory
$228.2m
CAGR 3-Years
-12%
CAGR 5-Years
10%
CAGR 10-Years
28%
Lantheus Holdings Inc
NASDAQ:LNTH
Inventory
$62m
CAGR 3-Years
21%
CAGR 5-Years
11%
CAGR 10-Years
14%
Merit Medical Systems Inc
NASDAQ:MMSI
Inventory
$326.6m
CAGR 3-Years
10%
CAGR 5-Years
9%
CAGR 10-Years
13%
No Stocks Found

Bioventus Inc
Glance View

Market Cap
667.9m USD
Industry
Health Care

Bioventus, Inc. global medical technology company which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. The company is headquartered in Durham, North Carolina and currently employs 1,200 full-time employees. The company went IPO on 2021-02-11. The firm is focused on developing and commercializing clinically and minimally invasive treatments that engage and enhance the body’s natural healing process. The Company’s portfolio of products includes OA joint pain treatment and joint preservation, bone graft substitutes and minimally invasive fracture treatment. The OA joint pain treatment and joint preservation is focused on orthopedics. Its bone graft substitutes (BGSs) offers portfolio of products including human tissue allografts and synthetics. Its BGS products can be used in conjunction with any orthopedic fixation and spinal fusion implant. They are designed to improve bone fusion rates following spinal fusion and other orthopedic surgeries and reduce the need for using the patient’s own bone.

BVS Intrinsic Value
12.2 USD
Undervaluation 34%
Intrinsic Value
Price
B

See Also

What is Bioventus Inc's Inventory?
Inventory
96.3m USD

Based on the financial report for Sep 27, 2025, Bioventus Inc's Inventory amounts to 96.3m USD.

What is Bioventus Inc's Inventory growth rate?
Inventory CAGR 5Y
23%

Over the last year, the Inventory growth was 7%. The average annual Inventory growth rates for Bioventus Inc have been 8% over the past three years , 23% over the past five years .

Back to Top